New drug could let Sun-Sensitive patients enjoy daylight again
NCT ID NCT06910358
First seen Sep 30, 2025 · Last updated Apr 28, 2026 · Updated 31 times
Summary
This study tests whether the drug bitopertin can safely increase the amount of time people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) can spend in sunlight without pain. About 183 participants aged 12 and older will receive either bitopertin or a placebo for 6 months. Researchers will measure changes in pain-free sun exposure and blood levels of a light-sensitive substance called PPIX.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPOIETIC PROTOPORPHYRIA (EPP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nantes - Hôtel Dieu, Service de dermatologie
Nantes, France, 44093, France
-
Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard
Paris, France, 75018, France
-
Charité - Universitätsmedizin Berlin, Institute of Allergology
Berlin, Germany, 12203, Germany
-
Children's Health Ireland (CHI)
Dublin, D12N512, Ireland
-
Clinical Research Centre, Ninewells Hospital & Medical School , NHS Tayside
Dundee, Scotland, DD1 9SY, United Kingdom
-
Erasmus MC
Rotterdam, The Netherlands, 3015 GD, Netherlands
-
Guy's and St Thomas' NHS Foundation Trust
London, England, SE1 9RT, United Kingdom
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Clinic de Barcelona
Barcelona, Spain, 08036, Spain
-
Instituto Dermatologico San Gallicano Istituti Fisioterapici Ospitalieri IRCCS
Roma, 53-00144, Italy
-
Karolinska University Hospital
Stockholm, Sweden, 141 86, Sweden
-
Klinikum Chemnitz gGmbH
Chemnitz, Saxony, 09116, Germany
-
Marvel Clinical Research
Huntington Beach, California, 92647, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
MetroBoston Clinical Partners
Boston, Massachusetts, 02135, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Photobiology Unit, Salford Royal Hospital
Salford, M6 8HD, United Kingdom
-
Remington-Davis Clinical Research
Columbus, Ohio, 43215, United States
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
UZ Leuven
Leuven, 3000, Belgium
-
University of Alberta
Edmonton, Alberta, T6G 2R3, Canada
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Miami Miller School of Medicine
Miami, Florida, 33146, United States
-
University of Texas Medical Branch
Galveston, Texas, 77550, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Wake Forest University
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.